Bristol-Myers Squibb Co. (BMY) Shares Bought by S&CO Inc.
S&CO Inc. raised its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,565 shares of the biopharmaceutical company’s stock after buying an additional 460 shares during the period. S&CO Inc.’s holdings in Bristol-Myers Squibb were worth $1,972,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of the company. Baxter Bros Inc. bought a new position in Bristol-Myers Squibb during the second quarter valued at approximately $895,000. Howland Capital Management LLC increased its position in Bristol-Myers Squibb by 3.2% in the second quarter. Howland Capital Management LLC now owns 38,272 shares of the biopharmaceutical company’s stock valued at $2,815,000 after buying an additional 1,178 shares in the last quarter. Park National Corp OH increased its position in Bristol-Myers Squibb by 0.6% in the second quarter. Park National Corp OH now owns 56,806 shares of the biopharmaceutical company’s stock valued at $4,178,000 after buying an additional 356 shares in the last quarter. Cullinan Associates Inc. increased its position in Bristol-Myers Squibb by 17.8% in the second quarter. Cullinan Associates Inc. now owns 585,796 shares of the biopharmaceutical company’s stock valued at $43,085,000 after buying an additional 88,700 shares in the last quarter. Finally, Boltwood Capital Management increased its position in Bristol-Myers Squibb by 1.7% in the second quarter. Boltwood Capital Management now owns 15,805 shares of the biopharmaceutical company’s stock valued at $1,162,000 after buying an additional 265 shares in the last quarter. 68.84% of the stock is owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.27% during midday trading on Tuesday, reaching $56.36. 9,818,891 shares of the company’s stock were exchanged. Bristol-Myers Squibb Co. has a one year low of $49.03 and a one year high of $77.12. The firm has a market cap of $94.19 billion, a PE ratio of 28.19 and a beta of 0.90. The stock’s 50-day moving average is $52.80 and its 200 day moving average is $62.81.
Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.12. The company earned $4.83 billion during the quarter, compared to the consensus estimate of $4.76 billion. Bristol-Myers Squibb had a net margin of 18.54% and a return on equity of 28.98%. Bristol-Myers Squibb’s revenue was up 21.0% compared to the same quarter last year. During the same period last year, the firm earned $0.39 earnings per share. Analysts anticipate that Bristol-Myers Squibb Co. will post $2.85 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/29/bristol-myers-squibb-co-bmy-shares-bought-by-sco-inc.html.
Several research firms have recently commented on BMY. SunTrust Banks Inc. downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $86.00 to $68.00 in a report on Friday, August 5th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Citigroup Inc. decreased their price objective on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, August 3rd. Piper Jaffray Cos. restated a “neutral” rating and set a $65.00 price target (down previously from $69.00) on shares of Bristol-Myers Squibb in a report on Monday, August 8th. Finally, Deutsche Bank AG reduced their price target on Bristol-Myers Squibb from $68.00 to $62.00 and set a “hold” rating on the stock in a report on Monday, August 8th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $67.51.
In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the completion of the sale, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.24% of the stock is currently owned by company insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related stocks with our FREE daily email newsletter.